Liver DiseasesNCT05088044
A Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi
A study testing training porogram in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
Trial summary
In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Liver Diseases
- What is being tested?
- training porogram
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 1 siteIndia
- Study dates
- 11 Nov 2021to 15 Apr 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- registered nurses working in general, semi-private and private ward nurses willing to participate
Who cannot join
- registered nurses who will not be present at the time of data collection. pull out staffs.
Trial locations and contacts
1 site in 1 country.
India1 site, 1 recruiting
- Recruiting
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070
Anajali Gautam, BSc, 01146300000, anjaligautam.9524@gmail.com
About this study
Official title: A Quasi Experimental Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi
In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members. this scoring will allow nurses to assess early deterioration and early ICU admission and at last nurses will be asked regarding the barriers or facilitators they faced while performing MEWS score.
- Conditions
- Liver Diseases
- Being tested
- training porogram
- Medical subject headings
- Liver Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
training porogramOther
training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
| Study group | Role | What they receive |
|---|---|---|
| staff nurses | Experimental | firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart Receives: Other: training porogram |
What is being measured
The primary outcome is the main question the study is designed to answer.
to assess the impact of MEWS on competency and self-efficacy of nurses before and after implementing MEWS
pre-test would be taken to assess previous level and post-test to measure the change in competency
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2021
- Study start11 Nov 2021
- Primary completion15 Apr 2022 (estimated)
- Study completion15 Apr 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- one group pre-test post-test design.
- Masking
- None (open label)
- Enrolment
- 82 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05088044
- Sponsor's protocol ID
- ILBS-Liver Disease-01
- Status last verified
- Oct 2021
- First submitted
- 11 Oct 2021
- Last updated
- 8 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Quasi Experimental Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi
- ClinicalTrials.gov ID
- NCT05088044
- Acronym / sponsor ID
- ILBS-Liver Disease-01
- Conditions
- Liver Diseases
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 82 participants (estimated)
- Lead sponsor
- Institute of Liver and Biliary Sciences, IndiaUniversity, hospital or other
- Study start
- 11 Nov 2021 (actual)
- Primary completion
- 15 Apr 2022 (estimated)
- Study completion
- 15 Apr 2022 (estimated)
- First posted
- 21 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members. this scoring will allow nurses to assess early deterioration and early ICU admission and at last nurses will be asked regarding the barriers or facilitators they faced while performing MEWS score.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- one group pre-test post-test design.
| Arm | Type | Receives |
|---|---|---|
| staff nurses | Experimental | Other: training porogramfirstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- registered nurses working in general, semi-private and private ward nurses willing to participate
Key exclusion criteria (1 listed)
- registered nurses who will not be present at the time of data collection. pull out staffs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| training porogramtraining on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration | Other | staff nurses |
Primary outcome
to assess the impact of MEWS on competency and self-efficacy of nurses before and after implementing MEWS
Time frame: 7 days
pre-test would be taken to assess previous level and post-test to measure the change in competency
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for Liver Diseases
Active, not recruitingPhase 2
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular Carcinoma
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Not yet recruitingPhase 3
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Recruiting
In-situ vs Ex-situ Liver Preservation
Liver Disease (Alcoholic or Not), Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing training porogram in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Anjali Gautam, BSc (01146300000, anjaligautam.9524@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
to assess the impact of MEWS on competency and self-efficacy of nurses before and after implementing MEWS (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2022; AzTrials last refreshed its copy on 1 Nov 2026.